Jacksonville, FLNCT06726161Now EnrollingIRB Ready

Hepatocellular Carcinoma (HCC) Clinical Trial in Jacksonville, FL

Access cutting-edge hepatocellular carcinoma (hcc) treatment through this clinical trial at a research site in Jacksonville. Study-provided care at no cost to qualified participants.

Sponsored by RayzeBio, Inc.

Quick Self-Assessment

See if you qualify for this Jacksonville location

Preparing your pre-screening questions…

Expert Care in Jacksonville

Access hepatocellular carcinoma (hcc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatocellular carcinoma (hcc) treatment provided free

Apply for This Jacksonville Location

Check if you qualify for this hepatocellular carcinoma (hcc) clinical trial in Jacksonville, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Jacksonville

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Jacksonville site if eligible
  4. 4Begin participation

About This Hepatocellular Carcinoma (HCC) Study in Jacksonville

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Sponsor: RayzeBio, Inc.

Who Can Participate

Inclusion Criteria

Age of at least 18 years at the time of signing the informed consent form (ICF)
Histologically/cytologically confirmed diagnosis of HCC.
Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B not amenable to locoregional therapy
Child-Pugh A
Eastern Cooperative Oncology Group (ECOG) performance status (PS 0-1)
Disease progression after 1 prior systemic therapy for unresectable HCC
Measurable disease per RECIST v1.1
Sufficient renal function
Adequate hematologic function
Adequate hepatic function
The subject must have recovered from toxicities related to prior treatments to ≤Grade 1, unless clinically nonsignificant and/or stable on supportive therapy
If HBV or HCV infection: Disease managed per local practice; antiviral treatment is allowed.
Gastric or esophageal varices previously treated with endoscopic therapy according to institutional standards are permitted if no clinically significant bleeding
For women of childbearing potential (WOCBP):
Negative serum pregnancy test within 48 hours prior to the first dose of RYZ811
Agreement to use barrier contraception and a second form of highly effective contraception
For sexually active males:
Must use a condom during intercourse
Male subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception
A condom is required to be used also by vasectomized men

Exclusion Criteria

Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellular cholangiocarcinoma
Prior liver transplantation
Known hypersensitivity to 68Ga, 225Ac or any of the excipients of RYZ811 or RYZ801
Portal vein tumor thrombosis classified as Vp4
Documented hepatic encephalopathy within 6 months of enrollment
Clinically meaningful ascites within 6 months of enrollment
Prior EBRT to the liver within 12 weeks prior to receiving RYZ811
Prior liver radioembolization
Previously treated central nervous system (CNS) metastasis without recovery from acute side effects
Documented history of idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) or pneumonitis
Uncontrolled significant intercurrent illness including, but not limited to:
QT interval corrected for heart rate using Fridericia's formula (QTcF) \>470 ms
Hemoglobin A1c (Hgb A1c) ≥8%
Uncontrolled hypertension
Dose Expansion only: Prior treatment with lenvatinib is exclusionary
Significant cardiovascular disease or heart failure
History of clinically significant bleeding
Prior participation in any interventional clinical study
Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
Have a history of primary malignancy within the past 3 years other than (1) HCC, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for \>3 years
Subject requires other treatment that in the opinion of the Investigator would be more appropriate than what is offered in the study
Pregnancy or breastfeeding Note: Additional criteria may apply and will be assessed by the study site

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Jacksonville?

Yes, this clinical trial (NCT06726161) has an active research site in Jacksonville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatocellular Carcinoma (HCC) Treatment Options in Jacksonville, FL

If you're searching for hepatocellular carcinoma (hcc) treatment options in Jacksonville, FL, this clinical trial (NCT06726161) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Jacksonville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma (hcc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatocellular carcinoma (hcc) clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Jacksonville, FL

See all liver cancer clinical trials recruiting in Jacksonville — not just this study.

Browse Liver Cancer Trials in Jacksonville →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Jacksonville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Jacksonville, FL